208 related articles for article (PubMed ID: 33160694)
1. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
Lee EK; Fader AN; Santin AD; Liu JF
Gynecol Oncol; 2021 Jan; 160(1):322-332. PubMed ID: 33160694
[TBL] [Abstract][Full Text] [Related]
2. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
Black JD; English DP; Roque DM; Santin AD
Womens Health (Lond); 2014 Jan; 10(1):45-57. PubMed ID: 24328598
[TBL] [Abstract][Full Text] [Related]
4. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
O'Connor CM; Taylor SE; Miller KM; Hurst L; Haanen TJ; Suhan TK; Zawacki KP; Noto FK; Trako J; Mohan A; Sangodkar J; Zamarin D; DiFeo A; Narla G
Cancer Res; 2022 Feb; 82(4):721-733. PubMed ID: 34921012
[TBL] [Abstract][Full Text] [Related]
5. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
7. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD
Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
9. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.
El-Sahwi KS; Schwartz PE; Santin AD
Expert Rev Anticancer Ther; 2012 Jan; 12(1):41-9. PubMed ID: 22149431
[TBL] [Abstract][Full Text] [Related]
10. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.
Bischof K; Knappskog S; Stefansson I; McCormack EM; Trovik J; Werner HMJ; Woie K; Gjertsen BT; Bjorge L
BMC Cancer; 2018 Jun; 18(1):684. PubMed ID: 29940909
[TBL] [Abstract][Full Text] [Related]
11. New Treatments for Recurrent Uterine Cancer.
Toboni MD; Powell MA
Curr Oncol Rep; 2021 Nov; 23(12):139. PubMed ID: 34735648
[TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Yadav G; Roque DM; Bellone S; Manavella DD; Hartwich TMP; Zipponi M; Harold J; Tymon-Rosario J; Mutlu L; Altwerger G; Menderes G; Ratner E; Buza N; Hui P; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Aug; 166(2):351-357. PubMed ID: 35641325
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it.
Menderes G; Lopez S; Han C; Altwerger G; Gysler S; Varughese J; Schwartz PE; Santin AD
Discov Med; 2018 Aug; 26(141):39-50. PubMed ID: 30265854
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy in the treatment of uterine serous carcinoma.
Schwab CL; Santin AD
Pharmacogenomics; 2015 Jan; 16(2):97-9. PubMed ID: 25616096
[No Abstract] [Full Text] [Related]
15. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers SK; Secord AA; Havrilesky L; O'Malley DM; Backes F; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi KS; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
J Clin Oncol; 2018 Jul; 36(20):2044-2051. PubMed ID: 29584549
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
Zeng X; Baba T; Hamanishi J; Matsumura N; Kharma B; Mise Y; Abiko K; Yamaguchi K; Horikawa N; Hunstman DG; Mulati K; Kitamura S; Taki M; Murakami R; Hosoe Y; Mandai M
Int J Cancer; 2019 Sep; 145(6):1635-1647. PubMed ID: 31228268
[TBL] [Abstract][Full Text] [Related]
19. Fallopian tube abnormalities in uterine serous carcinoma.
Steenbeek MP; Bulten J; Snijders MPLM; Lombaers M; Hendriks J; van den Brand M; Kraayenbrink AA; Massuger LFAG; Sweegers S; de Hullu JA; Pijnenborg JMA; Küsters-Vandevelde HVN; Reijnen C
Gynecol Oncol; 2020 Aug; 158(2):339-346. PubMed ID: 32409160
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
